Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

759 questions in 57 reviews · Colorectal

current versions

No studies 91 · 12%Ungraded 12 · 1.6%Very low 209 · 27.5%Low 229 · 30.2%Moderate 160 · 21.1%High 58 · 7.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Intervention NR Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ KRAS exon 2 MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 1.45 [1.01, 2.11]	5 studies · 1635 participants	Low
Intervention NR Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ KRAS exon 2 MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 32.35 [15.01, 69.7]	5 studies · 1635 participants	Moderate
Intervention NR Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ KRAS exon 2 MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 0.7 [0.53, 0.93]	3 studies · 968 participants	High
Intervention NR Quality of life · people with metastatic colorectal cancer ‐ KRAS exon 2 MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	HR 0.6 [0.48, 0.75]	6 studies · 1237 participants	Moderate
Intervention NR Overall survival · people with metastatic colorectal cancer ‐ extended RAS WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	HR 0.77 [0.67, 0.88]	4 studies · 1053 participants	High
Intervention NR Tumour response rate · people with metastatic colorectal cancer ‐ extended RAS WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 4.28 [2.61, 7.03]	4 studies · 1001 participants	Moderate
Intervention NR Overall survival · people with metastatic colorectal cancer ‐ KRAS exon 2 WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	HR 0.88 [0.8, 0.98]	12 studies · 4249 participants	High
Intervention NR Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ extended RAS WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ extended RAS WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ extended RAS WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ extended RAS WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life · people with metastatic colorectal cancer ‐ extended RAS WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	HR 1.13 [0.93, 1.36]	6 studies · 2023 participants	Moderate
Intervention NR Overall survival · people with metastatic colorectal cancer ‐ extended RAS MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	HR 1.09 [0.93, 1.28]	4 studies · 1768 participants	Moderate
Intervention NR Tumour response rate · people with metastatic colorectal cancer ‐ extended RAS MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 0.76 [0.55, 1.05]	3 studies · 840 participants	Moderate
Intervention NR Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ extended RAS MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ extended RAS MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Tumour response rate · people with metastatic colorectal cancer ‐ KRAS exon 2 WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 2.41 [1.7, 3.41]	12 studies · 4147 participants	High
Intervention NR Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ extended RAS MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Grade 3 to 4 neutropenia · people with metastatic colorectal cancer ‐ extended RAS MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life · people with metastatic colorectal cancer ‐ extended RAS MT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Progression‐free survival · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	2 studies · 1483 participants	High
Intervention NR Overall survival · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	2 studies · 1382 participants	High
Intervention NR Tumour response rate · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	2 studies · 1372 participants	Moderate
Intervention NR Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	1 study · 1267 participants	Low
Intervention NR Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	2 studies · 1341 participants	Low
Intervention NR Grade 3 to 4 rash · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	2 studies · 1341 participants	Low
Intervention NR Grade 3 to 4 neutropenia · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	2 studies · 1341 participants	Moderate
Intervention NR Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer ‐ KRAS exon 2 WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 2.45 [2.07, 2.89]	6 studies · 2771 participants	Moderate
Intervention NR Quality of life · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	1 study · 1298 participants	Moderate
Intervention NR Progression‐free survival · people with metastatic colorectal cancer Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	HR 1.02 [0.93, 1.12]	4 studies · 2189 participants	High
Intervention NR Overall survival · people with metastatic colorectal cancer Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	HR 0.84 [0.7, 1.01]	4 studies · 2189 participants	Moderate
Intervention NR Tumour response rate · people with metastatic colorectal cancer Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 1.36 [1.15, 1.62]	4 studies · 2184 participants	Moderate
Intervention NR Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 1.37 [1.09, 1.72]	4 studies · 2133 participants	Moderate
Intervention NR Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 1.06 [0.67, 1.67]	2 studies · 1673 participants	Very low
Intervention NR Grade 3 to 4 rash · people with metastatic colorectal cancer Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 47.53 [14.84, 152.19]	3 studies · 1951 participants	Moderate
Intervention NR Grade 3 to 4 neutropenia · people with metastatic colorectal cancer Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Quality of life · people with metastatic colorectal cancer Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Progression‐free survival · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	6 studies · 1651 participants	Moderate
Intervention NR Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ KRAS exon 2 WT Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	OR 1.84 [1.47, 2.32]	7 studies · 2909 participants	Moderate
Intervention NR Overall survival · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	5 studies · 1482 participants	High
Intervention NR Tumour response rate · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	4 studies · 1313 participants	Moderate
Intervention NR Overall grade 3 to 4 toxicity · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	6 studies · 1651 participants	Moderate
Intervention NR Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	6 studies · 1651 participants	Low
Intervention NR Grade 3 to 4 rash · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	6 studies · 1651 participants	Low
Intervention NR Grade 3 to 4 neutropenia · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	6 studies · 1651 participants	Moderate
Intervention NR Quality of life · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Progression‐free survival · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	2 studies · 181 participants	Low
Intervention NR Overall survival · people with metastatic colorectal cancer, not selected by KRAS status Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer (2017) · Cochrane	no estimate extracted	2 studies · 99 participants	Moderate